The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Abbreviated Breast MRI and Digital Tomosynthesis Mammography in Screening Women With Dense Breasts
Official Title: Comparison of Abbreviated Breast MRI and Digital Breast Tomosynthesis in Breast Cancer Screening in Women With Dense Breasts
Study ID: NCT02933489
Brief Summary: This randomized phase II trial studies how well abbreviated breast magnetic resonance imaging (MRI) and digital tomosynthesis mammography work in detecting cancer in women with dense breasts. Abbreviated breast MRI is a low cost procedure in which radio waves and a powerful magnet linked to a computer and used to create detailed pictures of the breast in less than 10 minutes. These pictures can show the difference between normal and diseased tissue. Digital tomosynthesis mammography is a procedure that uses multiple x-rays pictures of each breast to produce a 3-dimensional rendering of the entire breast. Combined screening with abbreviated breast MRI and digital tomosynthesis mammography may be a better method to screen women with dense breasts.
Detailed Description: PRIMARY OBJECTIVES: I. To compare the rates of detection of invasive cancers between the initial abbreviated breast (AB)-magnetic resonance (MR) and digital tomosynthesis mammography (DBT). SECONDARY OBJECTIVES: I. To compare the positive predictive value (PPV) of biopsies, call back rates, and short-term follow up rates after AB-MR and DBT on both the initial and 1 year follow up studies. II. To estimate and compare the sensitivity and specificity of AB-MR and DBT, using the 1 year follow up to define a reference standard. III. To compare patient-reported short-term quality of life related to diagnostic testing with AB-MR and DBT using the Testing Morbidities Index. IV. To compare willingness to return for testing with AB-MRI versus (vs) DBT within the recommended screening interval and explore factors associated with willingness to return for screening. V. To compare the tumor biologies of invasive cancers and ductal carcinoma in situ (DCIS) detected on AB-MR and DBT. VI. To estimate the incident cancer rate during 3 years following the year-1 AB-MR/DBT when patients return to standard screening. OUTLINE: Participants are randomized to 1 of 2 arms. ARM A (DBT, AB-MR): Participants undergo DBT followed by AB-MR for under 10 minutes on the same day or within 24 hours at baseline and then after 1 year. ARM B (AB-MR, DBT): Participants undergo AB-MR for under 10 minutes followed by DBT on the same day or within 24 hours at baseline and then after 1 year. After completion of study, patients are followed up at every 6 months for 3 years.
Minimum Age: 40 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: Yes
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
Huntington Memorial Hospital, Pasadena, California, United States
The Women's Imaging Center, Denver, Colorado, United States
Radiology Imaging Associates, Englewood, Colorado, United States
Norwalk Hospital, Norwalk, Connecticut, United States
Helen F Graham Cancer Center, Newark, Delaware, United States
Boca Raton Regional Hospital, Boca Raton, Florida, United States
Mayo Clinic in Florida, Jacksonville, Florida, United States
Diagnostic Center for Women LLC, Miami, Florida, United States
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Queen's Medical Center, Honolulu, Hawaii, United States
Northwestern University, Chicago, Illinois, United States
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States
Clinical Radiologists SC, Springfield, Illinois, United States
Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
The Community Hospital, Munster, Indiana, United States
Oncology Associates at Mercy Medical Center, Cedar Rapids, Iowa, United States
University of Kansas Cancer Center, Kansas City, Kansas, United States
University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States
Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Lahey Hospital and Medical Center, Burlington, Massachusetts, United States
Mercy Health Saint Mary's, Grand Rapids, Michigan, United States
West Michigan Cancer Center, Kalamazoo, Michigan, United States
Essentia Health Cancer Center, Duluth, Minnesota, United States
Mayo Clinic, Rochester, Minnesota, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
Riverview Medical Center/Booker Cancer Center, Red Bank, New Jersey, United States
Montefiore Medical Center-Einstein Campus, Bronx, New York, United States
Montefiore Medical Center - Moses Campus, Bronx, New York, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States
Novant Health Forsyth Medical Center, Winston-Salem, North Carolina, United States
Aultman Health Foundation, Canton, Ohio, United States
Case Western Reserve University, Cleveland, Ohio, United States
UHHS-Westlake Medical Center, Westlake, Ohio, United States
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Geisinger Medical Center, Danville, Pennsylvania, United States
Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States
University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
Rhode Island Hospital, Providence, Rhode Island, United States
Spartanburg Medical Center, Spartanburg, South Carolina, United States
Vanderbilt Breast Center at One Hundred Oaks, Nashville, Tennessee, United States
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
Baylor University Medical Center, Dallas, Texas, United States
Farmington Health Center, Farmington, Utah, United States
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
South Jordan Health Center, South Jordan, Utah, United States
Sentara Martha Jefferson Hospital, Charlottesville, Virginia, United States
University of Virginia Cancer Center, Charlottesville, Virginia, United States
Sentara Leigh Hospital, Norfolk, Virginia, United States
Sentara Norfolk General Hospital, Norfolk, Virginia, United States
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Seattle Cancer Care Alliance, Seattle, Washington, United States
University of Washington Medical Center, Seattle, Washington, United States
ThedaCare Regional Cancer Center, Appleton, Wisconsin, United States
Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
ProHealth D N Greenwald Center, Mukwonago, Wisconsin, United States
ProHealth Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, United States
ProHealth Waukesha Memorial Hospital, Waukesha, Wisconsin, United States
UW Cancer Center at ProHealth Care, Waukesha, Wisconsin, United States
Rwth Klinikum Aachen, Aachen, , Germany
Name: Christopher Comstock
Affiliation: ECOG-ACRIN Cancer Research Group
Role: PRINCIPAL_INVESTIGATOR